

09/26/03




09/26/03

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>	Attorney Docket No. 104035.269169
	First Inventor Dannhardt et al.
	Title 2-MERCAPTO-4,5-DIARYLIMIDAZOLE DERIVATIVES AND THE USE THEREOF AS CYCLOOXYGENASE INHIBITORS
	Express Mail Label No. EV 355445245 US

17497 U.S. PTO

10/672613



09/26/03

ADDRESS TO: **MAIL STOP PATENT APPLICATION  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450**

Transmitted herewith for filing in the United States Patent Office is a patent application for:

Inventors: Gerd Dannhardt and Linda Hahn

Assignee of this invention is

1. ☒ The Filing Fee has been calculated as shown below:  
 2. ☐ Applicant claims Small Entity Status. See 37 CFR 1.27.

	No. Filed	No. Extra	Small Entity		Large Entity	
			Rate	Fee 0	Rate	Fee 1
BASIC FEE				\$ 0		\$ 750
TOTAL CLAIMS:	23 - 20 =	3	X 9 =	\$ 0	x 18 =	\$ 54
INDEP CLAIMS:	1 - 3 =	0	X 42 =	\$ 0	x 84 =	\$ 0
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS PRESENTED				+140 = \$		+280 = \$
*If the difference in Column 1 is less than zero, enter "0" in Column 2.			TOTAL	\$	TOTAL	\$ 804

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Acct. No. 16-0605.

- a. ☐ Fees required under 37 CFR 1.16 (National filing fees).  
 b. ☒ Fees required under 37 CFR 1.17 (National application processing fees) including any extension of time fees under 37 CFR § 1.136(a) that are required for consideration of papers filed during prosecution.

☒ Form PTO-2038 is enclosed authorizing charge to credit card in the amount of \$ 804.00 for the filing fee.

3. ☒ Specification; Total Pages 78  
 4. ☐ \_\_\_\_\_ Sheets of Drawing(s) (35 USC 113)  
 5. ☐ Declaration and Power of Attorney; [Total Pages     ]  
     a. ☐ Newly executed (original or copy)  
     b. ☐ Copy from a prior application (37 CFR 1.63(d))  
         *(for continuation/divisional with Box 18 completed)*  
         i. ☐ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) & 1.33(b).  
 6. ☐ Application Data Sheet. See 37 CFR 1.76  
 7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Copy (CRF)
  - b. ☐ Request for Transfer of Computer Readable Form of Sequence Listing under 37 CFR § 1.821(e) and MPEP 2422.05 (must be compliant with new rules)
  - c. ☐ Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☐ Paper (\_\_\_ Pages)
  - d. ☐ Statements verifying identity of above copies

#### ACCOMPANYING APPLICATION PARTS

- 9. ☐ Assignment Papers (cover sheet & document(s) (including a check for the \$40.00 fee)
- 10. ☐ 37 CFR 3.73(b) Statement (*when there is an assignee*); ☐ Power of Attorney
- 11. ☐ English Translation Document (*if applicable*)
- 12. ☐ Information Disclosure Statement (IDS)/PTO-1449; \_\_\_ Copies of IDS Citations
- 13. ☐ Preliminary Amendment
- 14. ☒ Return Receipt Postcard (MPEP 503) (*Should be specifically itemized*)
- 15. ☐ Certified Copy of Priority Document(s) (*if foreign priority is claimed*)  
☒ Foreign Priority is claimed as German Application No. 101 14 775.9, filed March 26, 2001
- 16. ☐ Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i).  
Applicant must attach form PTO/SB35 or its equivalent.
- 17. ☐ Request for Early Publication Under 37 CFR § 1.219. Fee of \$300.00 is enclosed.
- 18. **If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:**
  - ☒ Continuation ☐ Divisional ☐ Continuation in Part (CIP)

of prior Application No: PCT/EP02/03264; Filed March 22, 2002

Prior Application Information: Examiner

Group/Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. **CORRESPONDENCE ADDRESS** **CUSTOMER NUMBER 00826**

Signature:

Attorney/Agent of Record: Andrew T. Meunier

Attorney/Agent Registration No. 40,726

**Alston & Bird LLP**

Bank of America Plaza

101 South Tryon Street, Suite 4000

Charlotte, NC 28280-4000

Tel Atlanta Office (404) 881-7000

Fax Atlanta Office (404) 881-7777

"Express Mail" mailing label number EV 355445245 US

Date of Deposit September 26, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Barbara Yates  
Barbara Yates